中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 10
Oct.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(10): 2273-2276

Further discussion on the antiviral treatment of chronic hepatitis B patients with indeterminate phase

DOI: 10.3969/j.issn.1001-5256.2023.10.001

  • Department of Microbiology and Center of Infectious Diseases，Peking University Health Science Center，Beijing 100191，China

More Information
  • Corresponding author: ZHUANG Hui， zhuangbmu@126.com （ORCID： 0000－0001－9119－6325）
  • Received Date: 2023-09-14
  • Published Date: 2023-10-30
    Abstract
  • This paper discusses further on the antiviral treatment of chronic hepatitis B patients with indeterminate phase. These patients have a high proportion of significant necroinflammation and fibrosis in the liver， and a higher risk of disease progression compared with those with true HBeAg－positive chronic hepatitis B virus （HBV） infection （formerly called the immune tolerance phase） or HBeAg－negative chronic HBV infection （formerly called the immune control phase）. Antiviral therapy may reduce the risk of HBV－related hepatocellular carcinoma in chronic hepatitis B patients with indeterminate phase.

     

    • FullText(HTML)
  • loading
    • References(21)
  • [1]
    Chinese Society of Hepatology, Chinese Medical Association. Experts opinon on expanding anti－HBV treatment for chronic hepatitis B[J]. Chin J Hepatol, 2022, 30( 2): 131－ 136. DOI: 10.3760/cma.j.cn501113－20220209－00060.

    中华医学会肝病学分会. 扩大慢性乙型肝炎抗病毒治疗的专家意见[J]. 中华肝脏病杂志, 2022, 30( 2): 131－ 136. DOI: 10.3760/cma.j.cn501113－20220209－00060.
    [2]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2022)[J]. Chin J Hepatol, 2022, 30( 12): 1309－ 1331. DOI: 10.3760/cma.j.cn501113－20221204－00607.

    中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华肝脏病杂志, 2022, 30( 12): 1309－ 1331. DOI: 10.3760/cma.j.cn501113－20221204－00607.
    [3]
    KUMAR M, SARIN SK, HISSAR S, et al. Virologic and histologic features of chronic hepatitis B virus－infected asymptomatic patients with persistently normal ALT[J]. Gastroenterology, 2008, 134( 5): 1376－ 1384. DOI: 10.1053/j.gastro.2008.02.075.
    [4]
    HSU YN, PAN CQ, ABBASI A, et al. Clinical presentation and disease phases of chronic hepatitis B using conventional versus modified ALT criteria in Asian Americans[J]. Dig Dis Sci, 2014, 59( 4): 865－ 871. DOI: 10.1007/s10620－014－3054－1.
    [5]
    European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67( 2): 370－ 398. DOI: 10.1016/j.jhep.2017.03.021.
    [6]
    MARTIN P, NGUYEN MH, DIETERICH DT, et al. Treatment algorithm for managing chronic hepatitis B virus infection in the United States: 2021 update[J]. Clin Gastroenterol Hepatol, 2022, 20( 8): 1766－ 1775. DOI: 10.1016/j.cgh.2021.07.036.
    [7]
    CHOI HSJ, TONTHAT A, JANSSEN HLA, et al. Aiming for functional cure with established and novel therapies for chronic hepatitis B[J]. Hepatol Commun, 2022, 6( 5): 935－ 949. DOI: 10.1002/hep4.1875.
    [8]
    DUSHEIKO G, AGARWAL K, MAINI MK. New approaches to chronic hepatitis B[J]. N Engl J Med, 2023, 388( 1): 55－ 69. DOI: 10.1056/NEJMra2211764.
    [9]
    YAO KF, LIU JC, WANG J, et al. Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone[J]. J Viral Hepat, 2021, 28( 7): 1025－ 1033. DOI: 10.1111/jvh.13511.
    [10]
    DUAN MH, CHI XL, XIAO HM, et al. High－normal alanine aminotransferase is an indicator for liver histopathology in HBeAg－negative chronic hepatitis B[J]. Hepatol Int, 2021, 15( 2): 318－ 327. DOI: 10.1007/s12072－021－10153－2.
    [11]
    HUANG DQ, LI XH, LE MH, et al. Natural history and hepatocellular carcinoma risk in untreated chronic hepatitis B patients with indeterminate phase[J]. Clin Gastroenterol Hepatol, 2022, 20( 8): 1803－ 1812.e 5. DOI: 10.1016/j.cgh.2021.01.019.
    [12]
    JIANG SW, LIAN X, HU AR, et al. Liver histopathological lesions is severe in patients with normal alanine transaminase and low to moderate hepatitis B virus DNA replication[J]. World J Gastroenterol, 2023, 29( 16): 2479－ 2494. DOI: 10.3748/wjg.v29.i16.2479.
    [13]
    WANG J, YAN XM, ZHU L, et al. Significant histological disease of patients with chronic hepatitis B virus infection in the grey zone[J]. Aliment Pharmacol Ther, 2023, 57( 5): 464－ 474. DOI: 10.1111/apt.17272.
    [14]
    XU XQ, WANG H, SHAN S, et al. The impact of the definitions of clinical phases on the profiles of grey－zone patients with chronic hepatitis B virus infection[J]. Viruses, 2023, 15( 5): 1212. DOI: 10.3390/v15051212.
    [15]
    JU YH, HAN GR, ZHANG P, et al. Staging and clinical characteristics of pregnant women with chronic hepatitis B virus infection: A retrospective cohort study from Nanjing, China[J]. J Obstet Gynaecol Res, 2023, 49( 10): 2427－ 2435. DOI: 10.1111/jog.15753.
    [16]
    LIU JC, WANG J, YAN XM, et al. Presence of liver inflammation in Asian patients with chronic hepatitis B with normal ALT and detectable HBV DNA in absence of liver fibrosis[J]. Hepatol Commun, 2022, 6( 4): 855－ 866. DOI: 10.1002/hep4.1859.
    [17]
    CHOI GH, KIM GA, CHOI J, et al. High risk of clinical events in untreated HBeAg－negative chronic hepatitis B patients with high viral load and no significant ALT elevation[J]. Aliment Pharmacol Ther, 2019, 50( 2): 215－ 226. DOI: 10.1111/apt.15311.
    [18]
    KIM GA, HAN S, CHOI GH, et al. Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients[J]. Aliment Pharmacol Ther, 2020, 51( 11): 1169－ 1179. DOI: 10.1111/apt.15725.
    [19]
    TENG W, CHANG TT, YANG HI, et al. Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines[J]. Hepatol Int, 2021, 15( 6): 1421－ 1430. DOI: 10.1007/s12072－021－10263－x.
    [20]
    SARIN SK, KUMAR M, LAU GK, et al. Asian－Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update[J]. Hepatol Int, 2016, 10( 1): 1－ 98. DOI: 10.1007/s12072－015－9675－4.
    [21]
    HUANG DQ, TRAN A, YEH ML, et al. Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase[J]. Hepatology, 2023, 78( 5): 1558- 1568. DOI: 10.1097/HEP.0000000000000459.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (534) PDF downloads(222) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return